© 2021 Personal Genomics Srl Data and images are for illustrative purposes only and may be changed at any time without notice

CLINICAL DIAGNOSTICS GENETIC TESTS FOR SOLID TUMOURS

Your solution provider in the world of genomics



How are the tests performed?

The test is performed starting with a liquid biopsy from a simple blood sample, or from a biopsy taken from different types of tumour tissue: fresh, frozen, formalin-fixed paraffinembedded (FFPE) or from fine needle aspiration (FNA). The analysis is conducted on nucleic acids extracted from the sample, possibly back-transcribed, amplified and sequenced using next generation techniques (NGS). The data obtained are assessed using a complex bioinformatic analysis to detect the presence of possible gene mutations.

Personal Genomics

offers 3 types of tests:

Personal Liquid Biopsy

Personal Cancer Check RNA

Personal Cancer Check DNA

What do the tests detect?

Personal Liquid Biopsy and Personal Cancer Check DNA: these allow mutational hotspot regions to be identified in the 16 tumour-specific genes most involved in tumour genesis. Personal Cancer Check RNA: this detects the presence of fusion genes in tumour tissue of specific RNA transcribed from 10 tumourspecific genes.

Positive result


The presence of one or more pathogenic variants was identified in at least one of the regions of the genes examined.



Negative result

No pathogenic variant was found in any region of the genes tested

WITH MEDICAL REFERRAL	Number of Repetitions	Number of Prescription s	Codes for Each
PERSONAL LIQUID BIOPSY	91.30.3*16	2	8
PERSONAL CANCER CHECK DNA	91.30.3*16	2	8
PERSONAL CANCER CHECK RNA	91.36.5*1 + 91.30.3*10	2	8 and 3





Personal Genomics Srl

Via Roveggia, 43b 37136 Verona (VR) Italy t+39 045 8202351 info@personalgenomics.it www.personalgenomics.it













We offer genetic testing for oncology diagnosis, prognosis assessment and increasingly customised therapy.

Why take the test?

The increase in incidence and mortality linked to the different tumour types shows the need to develop **new methods** that allow the **molecular profile of tumours** to be analysed in depth.

The test provides information on numerous gene regions with a simultaneous analysis of a single sample, providing important information on the genetic heterogeneity of the tumour.

With a **liquid biopsy**, the evolution of the **tumour can be** assessed over time.



Who are they for?

These genetic tests are designed for doctors and their patients, specifically:

Personal Cancer Check DNA: indicated to characterise the molecular profile of tumour DNA, support diagnosis, contribute towards the prognosis assessment, and provide guidance when choosing the most appropriate treatment for the patient.

Personal Liquid Biopsy: indicated to monitor tumour recurrence, which is an excellent follow-up parameter to identify a diagnosis even before there is clinical evidence.

This is a useful tool for patients with a family history of cancer related to mutations in the genes under investigation.

Personal Cancer Check RNA: indicated to determine the presence of fusion genes in tumour tissue to support diagnosis, contribute towards the prognosis assessment, and provide guidance for the patient when choosing the most appropriate treatment.

>99%

Reliability


Analytical sensitivity and specificity >99%

10 - 15 days

Reporting Time

The report will be produced in 10-15 working days

Biopsy Liquid or Tissue



The test is performed starting from a blood sample (liquid biopsy) or from tumour tissue (tissue biopsy).

Amplification and Next Generation Sequencing (NGS



The tumour's nucleic acids are isolated from the sample and analysed using PCR amplification and Next Generation Sequencing (NGS).

Data Analysis

Bioinformatic Analysis







Mutated gene sequences are evaluated using bioinformatic analysis.

Personal Genomics Report



Our team of experts will draw up a comprehensive tumour profile report, which will be delivered in 10 - 15 working days.